ghk-cu oral administration bioavailability Vs Injection: Complete Guide GHK-CU 50 mg - LIVV

Sincerely hope that we can have the honor to establish good partnerships with you

We identified key regions in the p53 transactivation domain (TAD) involved in FOXO4 binding and designed an optimized peptide inhibitor (CPP-CAND) with improved cell permeability

The injectable route makes more sense for wound healing and skin remodeling protocols where systemic distribution is the goal

Our approach combines complementary peptide technologies: GHK-Cu + Palmitoyl Tripeptide-1 & Palmitoyl Tetrapeptide-7 for skin, or GHK-Cu + Acetyl Tetrapeptide-3 for hair

Physician-initiated first-in-human clinical study using a novel angiogenic peptide, AG30/5C, for patients with severe limb ulcers